Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A.

(a) The tumor shows focal glandular architecture along with solid areas (100×, H&E). (b, c) The solid component exhibits prominent lymphocytic infiltrate with tumor heterogeneity (100×, H&E). (d) The ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gini F. Fleming, ...

Inside your pelvis is an organ that plays an important role in your period, ability to get pregnant, and carry a pregnancy. As with other parts of your body, sometimes cancer cells can grow there. The ...

A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...